A radiomics feature classification defining ovarian tumour aggression

  • Research type

    Research Study

  • Full title

    A radiomics feature classification approach to defining tumour aggressiveness in ovarian cancer

  • IRAS ID

    184497

  • Contact name

    Mubarik A Arshad

  • Contact email

    m.arshad@imperial.ac.uk

  • Sponsor organisation

    Imperial College London and Imperial College Healthcare NHS Trust

  • Duration of Study in the UK

    1 years, 4 months, 2 days

  • Research summary

    In the UK alone ovarian cancer affects around 7000 women each year and has poor prognosis, with high relapse rate and poor 10 year survival rate of about 35%. Poor survival is linked to advance clinical stage at presentation, sub-optimal tumour debulking and frequent development of chemotherapy resistance. Notably numerous scientifically interesting predictive/prognostic biomarkers have been identified, however, none are universally accepted for routine clinical use. It is against this background that we seek to develop a biomarker tool-kit based on the patient’s routine computed tomography (CT) scan – no significant additional cost to healthcare is envisaged since this will be part of routine care – that can predict disease aggressiveness (stage and extent) ultimately for use within the multidisciplinary team (MDT) setting in association with other metrics such as fitness of patient. CT, which by itself has limited prognostic information, forms an important first step in routine management of patients with ovarian cancer or when neoadjuvant therapy is recommended.

  • REC name

    West Midlands - Black Country Research Ethics Committee

  • REC reference

    15/WM/0237

  • Date of REC Opinion

    1 Jul 2015

  • REC opinion

    Favourable Opinion